Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Grigg, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grigg, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2002) 49, 75-80
© 2002 The British Society for Antimicrobial Chemotherapy

Supplement

Prophylaxis and treatment of patients with aspergillosis: an overview, including the Royal Melbourne Hospital experience

Andrew Grigg,*

Bone Marrow Transplantation Program, Royal Melbourne Hospital, Gratton Street, Parkville, VIC 3050, Melbourne, Australia

Abstract

Patients receiving allogeneic bone marrow transplants are at risk of developing Aspergillus infections. The pre-transplant risk factors for the development of invasive disease include prolonged neutropenia, colonization with Aspergillus sp. or a prior history of fungal infection. Post-transplant risk factors include severe graft-versus-host disease with concomitant high-dose corticosteroid therapy, and colonization with Aspergillus sp. The antifungal prophylaxis of selected high-risk pre-transplant patients at the Royal Melbourne Hospital includes granulocyte transfusions and AmBisome. In high-risk patients post-engraftment, prophylaxis consists of oral itraconazole, or if it cannot be tolerated, AmBisome. Antifungal prophylaxis is discontinued upon resolution of neutropenia, when prednisolone dose falls below 10 mg/day or when Aspergillus colonization disappears. Following this regimen, there has been only one death due to fungal infection in over 80 consecutive allograft patients. This patient was infected with an amphotericin B-resistant organism.

Notes

* Tel: 61-3-9342-7396; Fax: 61-3-9342-8022; E-mail: andrew.grigg{at}mh.org.au


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Toxicol Ind HealthHome page
M. A Klich
Health effects of Aspergillus in food and air
Toxicology and Industrial Health, October 1, 2009; 25(9-10): 657 - 667.
[Abstract] [PDF]

Home page
 J Antimicrob ChemotherHome page
J. Fortun, P. Martin-Davila, S. Moreno, R. Barcena, E. de Vicente, A. Honrubia, M. Garcia, J. Nuno, A. Candela, M. Uriarte, et al.
Prevention of invasive fungal infections in liver transplant recipients: the role of prophylaxis with lipid formulations of amphotericin B in high-risk patients
J. Antimicrob. Chemother., November 1, 2003; 52(5): 813 - 819.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.